↓ Skip to main content

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

Overview of attention for article published in Investigational New Drugs, June 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
1 X user
patent
2 patents

Citations

dimensions_citation
54 Dimensions

Readers on

mendeley
58 Mendeley